Compare F.N.B. Corporation Common Stock (FNB) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
F.N.B. Corporation Common Stock vs Smith & Nephew plc — how do they compare? F.N.B. Corporation Common Stock trades at $16.96 (market cap $6.07B), while Smith & Nephew plc trades at $28.24 (market cap $11.60B). The key difference: Smith & Nephew plc is the larger of the two by market cap, and F.N.B. Corporation Common Stock pays the higher dividend (3.05%). Which is the better fit depends on your goals — on Pluang, investors hold F.N.B. Corporation Common Stock for 0 Days and Smith & Nephew plc for 121 Days on average.
| FNB | SNN | |
|---|---|---|
Market Cap | $6.07B | $11.60B |
Volume | 5,600,609 | 971,836 |
Sector | Financials | Health |
52-Week High | $19.49 | $37.17 |
52-Week Low | $14.65 | $26.42 |
Typical Hold Time | 0 Days | 121 Days |
Enterprise Value | $10.61B | $14.63B |
Dividend Yield | 3.05% | 2.85% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FNB trades at $17.05, down 0.76% on the day, with a neutral technical signal. The stock shows solid fundamentals with a P/E of 10.15 and P/B of 0.89, indicating potential undervaluation. Recent earnings have been mixed, with Q2 2026 beating estimates but Q1 missing. Revenue remains stable at $1.77 billion for 2025, with a strong net income margin of 33.04%. Analyst sentiment is positive, with 13 buy ratings and a consensus price target of $20.80.
The outlook for FNB is cautiously optimistic, supported by strong profitability and a favorable analyst consensus. Key opportunities include potential upside to the price target and consistent dividend payments. Risks involve earnings volatility, as seen in recent quarters, and competitive pressures in the banking sector. Investors should weigh the attractive valuation against execution risks and market conditions.
SNN trades at $27.86, near a 52-week low, with a mixed technical signal. Revenue has grown from $5.2B in 2022 to $6.16B in 2025, with net income margin improving to 10.08%. Recent product launches like the EVOS PELVIC System highlight innovation, but the stock faces headwinds from analyst downgrades and CFO departure news.
The outlook is cautious; while fundamentals show steady growth and a reasonable P/E of 18.95, weak sentiment and technical pressure near lows suggest limited near-term upside. Risks include execution challenges and competitive threats, but long-term investors may find value if operational improvements materialize.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About F.N.B. Corporation Common Stock
F.N.B. Corporation is a diversified financial services holding company headquartered in Pittsburgh, Pennsylvania, operating through its lead subsidiary, First National Bank of Pennsylvania. It provides commercial banking, consumer banking, wealth management, and insurance through more than 350 banking offices across seven states and Washington, D.C.
Read more on FNB →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
